Vertex Pharmaceuticals Director Sells $639,598 in Stock (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX) Director Bruce Sachs unloaded 8,300 shares of the stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $77.06, for a total transaction of $639,598.00. Following the transaction, the director now directly owns 63,110 shares of the company’s stock, valued at approximately $4,863,257. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 0.10% during mid-day trading on Friday, hitting $76.83. 1,619,468 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 1-year low of $38.44 and a 1-year high of $89.96. The stock has a 50-day moving average of $78.21 and a 200-day moving average of $72.45. The company’s market cap is $17.887 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings data on Monday, July 29th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.08. The company had revenue of $310.80 million for the quarter, compared to the consensus estimate of $308.02 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. The company’s revenue for the quarter was down 25.7% on a year-over-year basis.
VRTX has been the subject of a number of recent research reports. Analysts at Needham & Company reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note to investors on Monday. They now have a $95.00 price target on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note to investors on Wednesday, October 16th. They now have a $84.00 price target on the stock. Finally, analysts at Barclays cut their price target on shares of Vertex Pharmaceuticals from $95.00 to $92.00 in a research note to investors on Wednesday, October 16th. They now have an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $89.68.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.